I now read the article by
Brandon Bernard: „Approach to oligometastatic prostate cancer“ This is published by the American Society of Clinical Oncology.
I think he describes our discussion quite well:
B. Bernard said...
„However, recent advances in imaging are identifying men with potentially isolated metastases, and mounting evidence suggests that durable control is attainable with treatment modalities targeting oligometastases, either with or without the use of systemic therapy........ there are currently no clear-cut data or validated tools to guide optimal therapy for an individual patient. One school of thought is to consider isolated lesions on imaging as representing the only sites of disease, where local therapy is sufficient. The other viewpoint is that oligometastatic disease is most likely also associated with micrometastatic disease; therefore, concurrent systemic therapy with localized therapy should be considered the optimal treatment......With this uncertainty, there is provider and patient bias toward certain treatments......„
He also mentions that micrometastases may take a long time to grow to visible mets. This could be an argument to radiate just the visible metastases:
„In the setting of postprostatectomy biochemical failure, the median time from PSA recurrence to metastases may be long (8 years in one study)":
Natural History of Progression After PSA Elevation Following Radical Prostatectomy Page 125.
George